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Introduction: Though the human fetus is exposed to placentally derived human chorionic gonadotropin (hCG) throughout gestation, the role of hCG on the fetal brain is
unknown. Review of the available literature appears to indicate that groups of women
with higher mean levels of hCG during pregnancy tend to have offspring with lower cerebral palsy (CP) risk. Given that newborn cerebral injury often precedes the development
of CP, we aimed to determine whether hCG may protect against the neurodegenerative
effects of neonatal brain injury.
Methods: We utilized the Rice–Vannucci model of neonatal cerebral hypoxia-ischemia
(HI) in postnatal day 7 mice to examine whether intraperitoneal administration of hCG
15–18 h prior, 1 h after or immediately following HI decrease brain tissue loss 7 days after
injury. We next studied whether hCG has pro-survival and trophic properties in neurons
by exposing immature cortical and hippocampal neurons to hCG in vitro and examining
neurite sprouting and neuronal survival prior and after glutamate receptor-mediated
excitotoxic injury.
Results: We found that intraperitoneal injection of hCG 15 h prior to HI, but not at or 1 h
after HI induction, resulted in a significant decrease in hippocampal and striatal tissue
loss 7 days following brain injury. Furthermore, hCG reduced N-methyl-d-aspartate
(NMDA)-mediated neuronal excitotoxicity in vitro when neurons were continuously
exposed to this hormone for 10 days or when given at the time and following neuronal
injury. In addition, continuous in vitro administration of hCG for 6–9 days increased
neurite sprouting and basal neuronal survival as assessed by at least a 1-fold increase in
MAP2 immunoreactivity and a 2.5-fold increase in NeuN + immunoreactivity.
Conclusion: Our findings suggest that hCG can decrease HI-associated immature
neural degeneration. The mechanism of action for this neuroprotective effect may partly
involve inhibition of NMDA-dependent excitotoxic injury. This study supports the hypothesis that hCG during pregnancy has the potential for protecting the developing brain
against HI, an important CP risk factor.
Keywords: cerebral palsy, human chorionic gonadotropin, fetal brain, ischemia, neuroprotection, brain injury,
excitotoxicity, chorionic gonadotropin
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INTRODUCTION

hippocampal and/or cortical neurons were continuously exposed
to hCG for one to up to 10 days, while we examined its effects
on neuronal survival and neurite sprouting prior and after
glutamate-mediated excitotoxic injury. Altogether, we found that
peripheral pretreatment with hCG reduces the effects of neonatal
cerebral HI in vivo and that direct hCG exposure to neurons
favors neuronal growth and survival under baseline and injurious conditions. The results described here support the hypothesis
that hCG can act as a neuroprotectant in the developing brain.
Future studies should aim at further exploration of the role of
hCG in brain development as well as the mechanisms involved
in hCG-mediated neuroprotection.

Human chorionic gonadotropin (hCG) is a placentally derived
hormone produced by the syncytiotrophoblast following
implantation. The human fetus is exposed to hCG throughout its
intrauterine development (1). Back in early 1980s, hCG receptors
(also known as lutropin receptors) were identified in multiple
fetal organs such as kidney, lung, and colon (2, 3), thus suggesting hCG’s role in fetal/neonatal growth and differentiation (4–7).
However, little progress has been made over the years in defining
this developmental role (4–7). Studies have shown that hCG
can cross the blood–brain barrier, and that hCG receptors exist
in fetal and neonatal rat brains (4–7). In vitro studies have also
demonstrated that hCG decreases neuronal cell death, promotes
the outgrowth of fetal neuronal cell processes, and supports the
proliferation of neural stem cells (5, 8, 9). Furthermore, hCG can
decrease ischemic brain injury in adult rodent models of stroke
and it has been shown to improve functional recovery following
spinal cord injury in rats (8, 10–14). Given the above evidence,
hCG may act as neuroprotectant against the neurodegenerative
effects of neonatal cerebral hypoxia-ischemia (HI).
Hypoxia-ischemia has been identified as a major cerebral
palsy (CP) risk factor (15–18). Given that almost 90% of the
CP-associated brain injuries occur in utero or around the time
of birth (19, 20), if hCG does indeed protect against hypoxicischemic brain injury, we would expect the offspring of women
with increased levels of hCG to have a lower risk of CP. To explore
this potential relationship, we searched the medical literature for
studies pertaining to maternal hCG levels during pregnancies of
singleton births and identified several distinct groups of women
with decreased mean hCG levels during pregnancy. We then
searched the literature for studies of CP risk for offspring born
to each of these distinct groups. We found that that the groups of
women with lower mean serum hCG tended to be at higher risk
for having children with CP. For example, mean maternal hCG
levels are significantly lower in women bearing boys, American
women of Asian-descent, women bearing boys with cryptorchidism and women who are obese (compared with women
bearing girls, American women of non-Asian descent, women
bearing boys without cryptorchidism, and women of normal
weight, respectively) (21–25). These same groups of women have
increased CP risk for their offspring compared with their counterparts (26–34). Thus, we indirectly identified a potential inverse
hCG–CP relationship which provides support to the hypothesis
that hCG has neuroprotective actions in the immature brain and
may play a role in diminishing CP risk.
In the present work, we sought to directly examine whether
hCG can serve as a neuroprotectant against the CP risk factor of
neonatal HI. We first utilized the Rice–Vannucci model of mouse
neonatal HI and investigated whether intraperitoneal (IP) hCG
administration to postnatal day 7 (P7) mouse pups at three treatment time points (15 h prior to hypoxia, 1 h prior to hypoxia and
immediately after hypoxia) decreases cerebral tissue loss 7 days
following injury. We then asked whether in vitro hCG exposure
favors the survival and growth of immature neurons and protects
them against N-methyl-d-aspartate (NMDA)-dependent excitotoxic injury. To explore this second aim, dissociated immature
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MATERIALS AND METHODS
Animals and Surgical Procedures

C57BL/6 (Charles River Laboratories Inc., Roanoke, IL, USA)
mice were kept under 12/12 light/dark cycles with ad libitum
access to food and water. Neonatal hypoxic-ischemic brain
injury was performed in male and female mouse pups at P7 as
previously described (35). Only pups with a body weight greater
than 3.0 g at the time of carotid surgery (P7) were used in this
study. Briefly, pups were anesthetized using 3% halothane for
induction and 2.5% halothane for maintenance (balance room
air). Under anesthesia, blood flow through the left carotid artery
was permanently interrupted by carotid artery cauterization
through an incision in the neck. Following carotid surgery, pups
were returned to the dam and allowed to recover for a minimum
of 3 h. Pups were then placed in pairs into individual thermoregulated hypoxia cylindrical chambers for 45 min at 36.5°C with 8%
oxygen. Each chamber contained a control pup and hCG-treated
pup. High-grade humidified 8% oxygen (±0.02%) balanced with
nitrogen was used. After completion of the hypoxia period, pups
were returned to the dam until the day they were euthanized at
postnatal day 14 (P14). In order to avoid potential confounders
related to changes in body temperature or other environmental
conditions, for each experiment, the saline control and hCGtreated animals were exposed at the same time to the hypoxia
chamber and to the same temperature conditions and for the
same duration of time. Similarly, every attempt was made to
equalize the surgical and post-surgical recovery conditions of the
control and hCG-treated groups.

hCG and Vehicle Injections

For all in vivo and in vitro experiments described below (except
as noted), the source of hCG was Sigma-Aldrich (St. Louis MO,
USA, Catalog no. CG10). When noted that a different source of
hCG was utilized, the source was Sigma-Aldrich (St. Louis MO,
USA, Catalog no. C0434). Reconstitution of hormone powder was
done in phosphate-buffered saline (PBS) as per manufacturer’s
recommendations to a concentration of 10,000 IU/mL. Drug was
then diluted to the specified concentrations in the corresponding
control in vitro (control salt solution or neurobasal media) and
in vivo (0.9% normal saline, NS) solutions.
A single 1,500 IU/kg IP injection of hCG was administered
to pups exposed to 45 min of hypoxia after carotid ligation and
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at three different time points: 15 h prior to hypoxia, 1 h prior to
hypoxia, or immediately after hypoxia. NS-injected littermates
were used as vehicle controls and exposed to the injury paradigm
at the same time as the neonatal pups injected with hCG. Every
attempt was made to segregate an equal number of males (M)
and females (F) to each treatment group to account for genderbased bias (total M/F; NS 18/14 and hCG 18/12). Drug or vehicle
was injected into the IP space using a 30-G needle attached to
a 100 μL Hamilton syringe (Hamilton, Reno, NV, USA). Given
hCG’s long half-life of about 36 h (1, 36, 37), we chose to administer a single IP dose to minimize potential toxic additive effects
of hCG. A dosage of 1,500 IU/kg of hCG was given since that is
the dose that was shown to be effective and safe in adult murine
stroke models (8).

was taken out of the group huddle. For the recording of body
temperature at a constant physiological temperature of 36.5°C
and following removal from physiological to room temperature
(Figures 2B–D), P7 pups treated with hCG (1,500 IU/kg) or
0.9% NS vehicle 15–18 h prior to temperature recording were
briefly anesthetized under halothane and the thermistor mini
recording probe was introduced into the rectum. Subsequently,
the probe was temporarily secured with adhesive tape to the
proximal portion of the mouse tail. The pups were then allowed
to fully recover from anesthesia for 30 min before any temperature recording. Anesthesia recovery and temperature equilibration were made in a thermoregulated hypoxia chamber set at
a constant temperature of 36.5°C and supplied by a constant
flow of humidified 21% FiO2 air. Following the 30-min postanesthesia period, the rectal temperature was recorded every
minute for 10 min followed by the animal being removed from
the thermoregulated 36.5°C chamber and into chamber set at
a constant room ambient temperature of 23°C in 21% FIO2. In
this chamber, the temperature was continuously recorded every
minute for 30 min before the probe was removed. In order to
minimize potential inter-recording variations among the control and hCG-treated groups, each single-temperature recording
session was carried in parallel using a control, saline-treated,
pup paired with an hCG-treated neonate. Every attempt was
made to segregate an equal amount of males and females to each
group (Control: 6 females/6 males; 1 h post-hCG: 3 females/2
males; 15–18 h post-hCG: 6 females/6 males). Postnatal day 7
mouse pups only weighing 3 g or more were included in these
experiments and the average weight did not significantly differ
among groups (Control: 3.5 ± 0.10 g, N = 12; 1 h post-hCG:
3.4 ± 0.13 g, N = 5; 15–18 h hCG, 3.6 ± 0.14 g, N = 12).

Histology and Tissue Injury Quantification

At 7 days following HI, P14 mice pups were deeply anesthetized
with pentobarbital (150 mg/kg) and perfused transcardially
with ice-cold PBS containing 3 U/mL heparin. Brains were
removed and immersion-fixed in 4% (w/v) paraformaldehyde
(PFA) in 0.1 M phosphate buffer (pH 7.4) at 4°C for 24 h, and
then cryoprotected in 30% (w/v) sucrose in 0.1 M phosphate
buffer until freezing in powdered dry ice and sectioned into
50 µm coronal sections with a freezing sliding microtome. The
uninjured, contralateral right hemisphere was marked by nicking it with a razor blade. A set of coronal brain sections (spaced
50 µM apart) beginning at the genu of the corpus extending to
the mid body of the dorsal hippocampus were mounted in DAPI
mounting medium (Vector Labs) and imaged via Nanozoomer
(Hamamatsu Photonics). Percentage of tissue loss was calculated
by comparing the cortex, striatum, and hippocampus of the
injured hemisphere (left) to the uninjured hemisphere (right)
using the Nanozoomer imaging software as previously described
(38, 39). Three coronal sections per quantification area per animal
were used for each of the brain regions studied. Striatum volume
was calculated using those sections containing the striatum at
the level of the genu of the corpus callosum. Hippocampal injury
was determined by analyzing sections containing all layers of the
dorsal hippocampal formation. Cortical areas were analyzed on
the sections that contained the dorsal hippocampus. The investigators were blinded to the treatment during area analysis.

Determination of Serum hCG
Concentration

Serum was extracted from P7 pups via cardiac puncture 1 h
or 15–18 h following IP hCG administration. Approximately
50–70 µL of blood was obtained from each pup. Blood samples
were immediately placed in serum separating cold microcentrifuge tubes and centrifuged at 10,000 rpm for 15 min. Serum
samples were then loaded at 1:15 dilution into a 96-well commercially available sandwich hCG enzyme-linked immunosorbent assay (ELISA; ab100533, Abcam, Cambridge, MA, USA).
Standard curve and serum samples were probed using the ELISA
kit in duplicate and according to the manufacturer’s instructions.
Conversion from ng/mL to IU/mL was determined using this
assay and generating a second dilution curve from a known
concentration of the hCG employed in the animal and cell experiments (CG10, Sigma, St. Louis, MO, USA).

Determination of Neonatal Mouse Body
Temperature

Body temperature recordings were obtained by transiently
introducing a miniature thermistor recording probe coated
with triple antibiotic lubricating gel (TH-10Kmp thermistor,
Cell MicroControls, Norfolk, VA, USA) into the rectum of a P7
C57BL/6 mouse and connected to a 2 channel micro temperature controller (mTCII, Cell MicroControls, Norfolk, VA, USA).
For the determination of body temperature during group huddle (Figure 2A), a consistent five-mouse pup huddle was used.
Animals were injected intraperitoneally with 0.9% NS-control
solution or 1,500 IU/kg of hCG 1 h or 15–18 h prior to temperature recording. Recording of huddle pup temperature was done
immediately and approximately within 20 s after the animal
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Dissociated Cortical and Hippocampal
Cultures and Ibotenic Acid-Mediated
Excitotoxic Assay

The cortex and hippocampus were microdissected from
embryonic day 18 C57BL/6 embryos and incubated in Hank’s
balanced salt solution with 2.5% (10×) trypsin for 7 min at
37°C. Following trypsin incubation, cells were dissociated into
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a homogenous suspension by gentle pipetting tissue up and
down 15–20 times utilizing a sterile 1mL pipette. The dissociated neurons of cortices and hippocampi were resuspended
after cold centrifugation (4°C; 1,500 rpm) in neurobasal media
and placed in 24-well plates precoated with Poly-l-Lysine. To
avoid plating neurons at different densities in different wells,
cells were plated at the same time from a common dissociated
neuronal preparation at a calculated equal neuronal concentration of 100,000 cells/well; all neurons for a given experiment
were plated simultaneously and treated equally prior to any
drug or injury treatment. Although we did quantify the amount
of neurons in each well, routine visual inspection of neurons
under phase contrast microscopy prior to exposure to any form
of treatment appeared to show consistent density, growth, and
morphology across all wells. Cells were maintained in neurobasal media plus 1X B-27 supplement, 0.5-mM l-glutamine with
penicillin-streptomycin, and 50% of the media was replaced
every 3–4 days. Neurons were examined in the presence or
absence of hCG (diluted in neurobasal media at a concentration of 2 IU/mL unless otherwise specified). At DIV12, cultured
neurons were washed with a controlled salt solution (CSS)
containing 120-mM NaCl, 5.4-mM KCl, 1.2 mM CaCl2, 15-mM
glucose, and 25-mM Tris–HCl, pH = 7.40, at room temperature.
Magnesium was omitted to avoid blockade of the NMDA receptor channels. Following the wash, cells were exposed to 50-µM
Ibotenic acid (IBO) with 100-µM glycine in CSS or CSS alone
for 5 min then washed and incubated in neurobasal media for
24 h prior to lactase dehydrogenase (LDH) assay or cytological
assessment as previously described (40).

experiment and treatment condition. Every attempt was made
to select the same approximate location in the culture for each
experimental condition in a treatment-blinded fashion. Areas
were chosen away from the edge of the 1.6-cm culture and at
approximately the 3, 6, 9, and 12 o’clock location. The amount
of immunofluorescence was quantified utilizing ImageJ analysis
software by thresholding the immunofluorescence of control
conditions and automating the analysis of NeuN or MAP2
immunofluorescence per region for all cultures while keeping the
same threshold and image settings (41). Data were expressed as
the average amount of immunofluorescence per fixed unit area.
A single N-value represents average stain quantified per area per
a single culture well.

Chronic hCG Exposure/IBO Assay
Procedure

Dissociated cortical and hippocampal late embryonic (E18)
neurons were exposed to 2 IU/mL of hCG beginning at 3 days
(DIV3) after plating and continuing until 24 h post-injury at
DIV13 (totaling 10 days of hCG exposure). Excitotoxic injury
was achieved by transient, 5-min, 50-µM IBO administration at
DIV12 as previously described (40). An hCG concentration of 2
IU/mL was first chosen given that this is the calculated average
concentration of hCG present in human fetal amniotic fluid
(42–44). Neuronal cell viability was measured by quantifying the
amount of neurite degeneration via MAP2 staining 24 h postIBO administration and by examining lactate dehydrogenase
activity (described above) in the culture media 24 h following
injury.

Lactate Dehydrogenase Assay

Acute hCG Exposure/IBO Assay
Procedure

At 24-h post-excitotoxic injury with IBO or prior to PFA fixation, media from individual wells of cortical and hippocampal
neuron cultures were collected and assayed for LDH using a
cytotoxicity detection kit (Roche) as previously described (38).
Briefly, 100 µL of culture medium per well/sample in duplicate
was incubated with gentle shaking with the kit reagents for
30 min in the dark, after which the product was measured at
490 nm utilizing a standard 96-well microplate reader (Bio-Tek
Instruments). Following collection of conditioned media for
LDH, cells were fixed with 4% PFA in phosphate buffer for
30 min at room temperature. After washing with PBS, cells
were permeabilized with PBS-X, blocked in normal serum, and
probed for immunocytochemistry.

Dissociated E18 cortical neurons were allowed to grow for 12 days
in the absence of hormone and then were transiently exposed to
50-µM IBO for 5 min in the absence and presence of hCG at
concentration of 2 and 20 IU/mL. Control neurons were exposed
only to the control salt solution. hCG exposure continued for 24
h after injury when the neurons were fixed in PFA and processed
for MAP2 immunocytochemistry.

High-Dose hCG Exposure

In a separate experiment and in order to evaluate the effects
of high-dose hCG on neuronal cell count and neurite sprouting, we continuously exposed neurons for 6 days to 2, 10, and
100 IU/mL of hCG diluted in culture media starting at DIV3.
After the hCG-exposure period, neurons were fixed in PFA and
processed for MAP2, NeuN and GFAP immunocytochemistry.

In Vitro Immunofluorescence
Quantification

Quantification of neurons and neuronal processes was achieved
by staining PFA-fixed cortical and hippocampal neurons with
a mouse MAP2 antibody (1:1,000, Millipore) or NeuN Alexa
Fluor®488 conjugated antibody (1:100, Millipore). Sample digital
images of MAP2 and NeuN stained neurons in control and
hCG-treated neuronal cultures were obtained. For quantification,
the analysis area (1 mm × 1 mm region) per digital image and
the number of images and image characteristics (3–4 images/
neuronal culture well) in the culture well were the same for each
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Statistics

Data are presented as mean ± SEM and were compared using
one-way ANOVA followed by Bonferroni test for multiple comparisons, one-sample t-test for hypothetical value comparisons,
and one or two-tailed Student’s t-test for two-group comparisons
unless otherwise specified. Statistical significance was set at 0.05
where *p < 0.05 and **p < 0.01. Statistics were performed using
GraphPad Prism (GraphPad software).
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RESULTS

regions examined. We did not observe any deaths associated with
hCG or saline injection and there were no significant changes in
pup weight between control animals (4.10 ± 0.1 g; N = 32) and
hCG-treated animals (4.08 ± 0.1 g; N = 30).

Pretreatment with hCG Protects the
Immature Brain from Hypoxic-Ischemic
Neonatal Neurodegeneration

hCG Exposure Does Not Affecting Body
Temperature

Term-equivalent C57BL/6 mouse pups were subjected to unilateral carotid ligation followed by 45 min of 8% hypoxia. As shown
in Figures 1A,B, IP administration of 1,500 IU/kg of hCG 15
h prior to neonatal global cerebral hypoxia resulted in a 36%
reduction in the amount of hippocampal tissue loss (% change
in left vs. right brain; NS: 44.5 ± 3.9; hCG: 28.5 ± 3.8; p = 0.008)
and a 29% reduction in striatal tissue loss (% change in left vs.
right brain; NS: 23.5 ± 3.1; hCG: 16.7 ± 2.2; p = 0.049) 7 days
after HI compared to saline-injected littermate controls. Next,
1,500 IU/kg of hCG or saline control solution was injected into
P7 pups either 1 h prior to hypoxia or immediately after hypoxia
exposure. As shown in Figures 1C,D, IP administration of hCG
given at these two time periods did not result in protection
against cerebral degeneration following HI in any of the cerebral

Given that hCG receptors are implicated in the regulation of the
central hypothalamic-pituitary-gonadal axis in adult rodents
(11), and understanding that neonatal hypothermia has been
shown to reduce cerebral tissue loss following HI (45), we
asked whether the neuroprotective actions of peripheral hCG
administration are attributed to a decrease in body temperature.
Intraperitoneal injection of 1,500 IU/kg of hCG 1-h or 15–18-h
post-hormone injection did not alter neonatal P7 pup temperature when temperature was obtained in mouse huddle conditions
compared with saline-treated littermates (Figure 2A; saline
control: 33.08 ± 0.34°C; 1 h post-hCG: 33.28 ± 0.18°C; 15–18 h
post-hCG: 32.90 ± 0.42°C; N = 5/condition). Similarly, pup body

Figure 1 | In vivo hCG IP administration protects the brain from the neurodegenerative effects of HI in a time-dependent manner. (A) The relative tissue losses
[calculated by the percent difference between left (L) ipsilateral, ischemic, and right (R) contralateral, non-ischemic, hemisphere] in the hippocampus, striatum and
cerebral cortex 7 days after carotid ligation followed by 45 min of hypoxia from NS-injected vs. hCG-injected (1,500 IU/kg) P7 mouse pups treated 15 h prior to HI.
hCG treatment decreased hippocampal (NS 44.5 ± 3.9% vs. hCG 28.5 ± 3.8%) and striatal (NS 23.5 ± 3.1% vs. hCG 16.7 ± 2.3%) tissue loss following HI. Actual
area values (average ± SEM mm2) in left vs. right hippocampus are 1.8 ± 0.12 vs. 0.97 ± 0.10 mm2 for NS and 1.8 ± 0.14 vs. 1.3 ± 0.10 mm2 for hCG. Average
area values in left vs. right striatum are 3.3 ± 0.19 vs. 2.4 ± 0.12 mm2 for NS and 3.0 ± 0.16 vs. 2.5 ± 0.12 mm2 for hCG. (B) Representative coronal digital
micrographs taken from injured NS- and hCG-injected animals treated 15 h prior to HI. Note the ex-vacuo dilatation of the left, ischemic, cerebral ventricle, and
relative atrophy of the left hippocampal formation in the NS group compared with the contralateral brain. (C,D) IP injection of hCG (1,500 IU/kg) 1 h (C) or
immediately after (D) neonatal injury in P7 neonatal pups did not protect against the neurodegenerative effects of HI. Error bars show SE; *p < 0.05 and **p < 0.01.
hCG, human chorionic gonadotropin; HI, hypoxia-ischemia; Hipp, hippocampus; IP, intraperitoneal; NS, normal saline; Str, striatum.
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Figure 2 | IP administration of hCG (1,500 IU/kg) does not alter neonatal pup body temperature. (A,B) Body temperature as assessed by rectal temperature in
neonatal P7 mouse pups did not change 1 h or 15–18 h following hCG injection when examined during pup huddling or during a constant physiological ambient
temperature of 36.5°C. (C) Removal of individual neonatal P7 pups from physiological (36.5°C) to room temperature (23°C) produced a gradual decline in body
temperature. hCG administration did not alter the rate of temperature decline upon ambient temperature exposure when examined 15–18 h after drug injection.
Statistical comparisons were performed by repeated measures ANOVA followed by Bonferroni post hoc test. (D) Second-degree polynomial curve fit calculated
from data in (C), demonstrating nearly identical temperature drops upon change in ambient temperature from 36.5 to 23°C in NS control and hCG-treated neonatal
P7 pups. hCG, human chorionic gonadotropin; IP, intraperitoneal.

temperature in mice exposed to a constant physiological ambient temperature of 36.5°C did differ between mice exposed to
saline and those exposed to 1,500 IU/kg of hCG 15–18 h prior to
temperature recording (Figure 2B; saline control: 36.7 ± 0.1°C;
15–18 h post-hCG: 36.6 ± 0.1°C; N = 7/condition). Since neonatal mouse body temperature is highly dependent on ambient
temperature (46, 47), we wanted to rule out the possibility of hCG
altering the adaptation of the mouse neonate to rapid changes in
ambient temperature. To examine this question, paired 15–18 h
post-hCG- and saline-injected mouse pups were rapidly transitioned from a 30-min period of constant physiological ambient
temperature of 36.5°C to room ambient temperature (23°C) while
body temperature was continuously recorded for 30 min. Under
these conditions, pup temperature gradually declined to a nearly
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identical degree and pattern between hCG and saline-treated
groups (Figures 2C,D). We did not examine hCG’s effect on
brain temperature prior and following HI and thus, a confounding effect of hCG on cerebral temperature in the injured neonate
cannot be conclusively ruled out. Nevertheless, the presented
data above suggest that hCG alone does not affect pup body
temperature. Therefore, it is less likely that intrinsic differential
effects of hCG on body temperature contribute significantly to
the neuroprotective effect observed upon peripheral injection of
hCG 15 h prior to HI.
Importantly and as shown in Figure 2C, the body temperature of P7 pups is tightly dependent on ambient temperature.
Therefore, transient secondary hypothermia can occur when
animals are removed from the hypoxia chamber and placed back
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in vitro experiments. Although the concentration of hCG in cord
blood and amniotic fluid varies according to gestational age,
prior studies report cord blood and amniotic fluid hCG levels in
term neonates to be around 0.2 and 0.4 IU/mL, respectively, with
amniotic fluid levels averaging about 2 IU/mL during the third
trimester of pregnancy (43, 48). Taken together, the above serum
hCG levels found following a single-IP hCG dose of 1,500 IU/mL
appear to be within the range observed in humans.

with the dam. In order to minimize this potential confounder,
hCG- and saline-treated animals were exposed to the hypoxiachamber simultaneously and were placed back with the dam
following hypoxia as a group while making every attempt to have
an equal proportion of control and hCG-treated pups in each
litter. Qualitatively, we did not observe differential treatment in
the behavior of the mother toward either treatment condition
with the dam resuming nesting and feeding of her pups almost
immediately after being placed back in their cage.

Chronic In Vitro Exposure of Immature
Cortical and Hippocampal Neurons to hCG
Protects against NMDA-Dependent
Excitotoxic Injury

Serum hCG Levels 1 and 15–18 h Post
1,500 IU/kg hCG Injection are Similar
to Those Found in the Amniotic
Fluid of Term Human Neonates

We then investigated whether chronic (10-day) exposure of
immature neurons to 2 IU/mL hCG, a concentration of hormone
found in human amniotic fluid (42–44), protects against NMDAmediated excitotoxic neurodegeneration. Chronic hCG exposure
resulted in a significant decrease in neuronal NMDA-mediated
excitotoxicity; this is demonstrated by the relative increase in
the percent of MAP2 immunoreactivity (IR) in hippocampal
(0.79 ± 0.3 vs. 25.5 ± 8.4%; p = 0.021) and cortical (11.74 ± 4.4
vs. 77.1 ± 8.8%; p = 0.001) neuronal cultures 24 h following
excitotoxic insult with IBO (Figures 4A–C) as compared with
non-hCG exposed neurons. Similarly, hippocampal and cortical
cultures chronically exposed to hCG demonstrated a significant
decrease in the percent elevation of LDH activity in the culture
media 24 h following IBO exposure (92.6 ± 4.8 vs. 58.3 ± 9.4%;
p = 0.015; and 88.4 ± 5.4 vs. 53.3 ± 6.2%; p = 0.001, respectively;
Figure 4C). The combination of these findings (increased neurite
preservation and decreased LDH activity) suggests that prolonged
exposure (beginning before injury) of hCG (2 IU/mL) directly
to immature dissociated brain neurons is capable of decreasing
NMDA-mediated excitotoxic neurodegeneration.

In order to have a better understanding of how the hCG dose
used in this study relates to the serum levels commonly found in
human cord blood and amniotic fluid, we extracted serum from
the blood of P7 animals injected with 1,500 IU/kg of hCG 1 and
15–18 h after hormone injection and determined their serum
hCG levels (in ng/mL and IU/mL) utilizing a commercially
available serum hCG ELISA assay. As shown in Figure 3, the
mean ± SEM serum hCG concentrations in the 1 and 15–18 h
post-hCG groups were 31.4 ± 3 and 29.8 ± 4 ng/mL, respectively.
These levels corresponded to 0.41 ± 0.04 IU/mL (1 h post-hCG)
and 0.39 ± 0.06 IU/mL (15–18 h post-hCG) when the internal
standard curve of the ELISA assay was compared with a dilution curve generated by the hCG used in this study’s animal and

Acute In Vitro hCG Exposure Protects
Neurons against NMDA-Mediated
Excitotoxic Neurodegeneration

We then investigated whether acute exposure of immature
neurons to low-dose hCG (2 IU/mL) or to high-dose hCG (20
IU/mL) protects against NMDA-mediated excitotoxic neurodegeneration. hCG administered at the time and 24 h following IBO
exposure significantly reduced IBO-mediated cortical neurite
neurodegeneration by 55% (p < 0.01) at 2 IU/mL hCG and by 46%
(p < 0.05) at 20 IU/mL hCG when compared with their respective
non-hCG-treated injured neuronal controls (Figures 5A–E). The
neuroprotection seen at 2 IU/mL hCG concentration vs. that seen
at 20 IU/mL hCG concentrations was not significantly different
from each other (Figure 5E). These data indicate that hCG, when
administered directly to neurons at the time of injury is able to
reduce NMDA-mediated neuronal excitotoxicity.

Figure 3 | Serum hCG concentrations obtained from neonatal P7 mouse
pups 1 and 15–18 h following IP 1,500 IU/kg hCG injection. Serum hCG
levels (calculated in ng/mL) were obtained utilizing a commercially available
hCG ELISA assay (ab100533, Abcam, Cambridge, MA, USA). Conversion to
IU/mL was done using this assay and a known concentration of the hCG
source employed in the animal and cell experiments (CG10, Sigma, St. Louis,
MO, USA). No hCG IR was observed in control, NS-injected, mouse serum
indicating no mouse protein cross-reactivity. The serum hCG concentration
did not appear to differ significantly between 1 h (31.4 ± 3 ng/mL;
0.41 ± 0.04 IU/mL) and 15–18 h (29.8 ± 4 ng/mL; 0.39 ± 0.06 IU/mL)
post-IP hormone injection. These serum concentrations are similar to those
found in human term amniotic fluid (43, 48). hCG, human chorionic
gonadotropin; IP, intraperitoneal, IR, immunoreactivity; NS, normal saline.
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Early (DIV3) High-Dose hCG Exposure
In Vitro Increases Basal Neuronal Survival

We also studied the potential neurotrophic effects of hCG by
examining basal neuronal survival of immature cortical neurons
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Figure 4 | In vitro chronic, 10-day, hCG exposure to immature cortical and hippocampal neurons is not toxic and protects them from NMDA-dependent
excitotoxic injury. (A,B) MAP2 fluorescence following immunocytochemical staining of dissociated cortical and hippocampal neurons exposed to control vs. 2 IU/mL
of hCG for 9 days prior and 24 h following IBO (50 µM; IBO) exposure. Prolonged hCG did not appear to affect neuronal survival. Note also the relative preservation
of neurites in hCG-exposed neurons after IBO exposure (most noticeable in cortical neurons) compared with control (CSS; controlled salt solution). (C) Quantitative
bar graph analysis of the effects of hCG on neuronal survival as a measure of LDH activity in the neuronal media or MAP2 IR in control and hCG-treated neuronal
cultures 24 h after injury with IBO. Cortical and hippocampal neurons exposed to hCG demonstrated a reduction in IBO-mediated increases in LDH activity and a
relative preservation of neurite staining compared with non-hCG-treated cells. Scale bars = 165 µm. Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human
chorionic gonadotropin; IBO, ibotenic acid; IR, immunoreactivity; LDH, lactase dehydrogenase.

exposed to high concentrations of hCG starting at DIV3. Sixday hCG treatment at 100 IU/mL concentration resulted in a
visible (Figure 6A) and quantitative (Figure 6B) 1.05 ± 0.2-fold
(p = 0.034) increase in neurite sprouting as seen in MAP2
immunofluorescence staining and a quantitative 2.5 ± 0.5-fold
(p = 0.038) increase in neuronal cell count as seen in NeuN
immunofluorescence staining.
Neuronal MAP2 + cell processes in high-dose hCG-treated
neurons appeared longer and more complex suggesting the
possibility of an hCG-mediated increased in neurite sprouting
(Figure 6A). Interestingly, we also observed daily progressive
grouping of neurons surrounded by morphologically appearing
astrocytes only in the cultures exposed to high 100 IU/mL hCG.
Triple staining of these cultures with MAP2, NeuN, and GFAP
confirmed the increased presence of GFAP + astrocytes 6 days
following high-dose hCG exposure. In contrast, GFAP + staining
was almost completely absent in non-hCG-treated neurons at this
time in culture (Figure 6A). Similarly, in a separate experiment
utilizing a different source of hCG, we observed a significant
1.3 ± 0.36-fold (p = 0.002; N = 3; graph not shown) increase in
Frontiers in Pediatrics | www.frontiersin.org

MAP2-IR following continuous 9-day hCG administration at a
concentration of 500 ng/mL. Taken together, these data support
the conclusion that prolonged, direct exposure of neurons to high
hCG concentrations under basal conditions promotes neuronal
survival and potentially increases neuronal sprouting.

DISCUSSION
The in vivo study results suggest that hCG decreases HI brain
injury when the neonate is exposed to hCG before the hypoxicischemic event occurs. When hCG was peripherally administered
many hours (≥15 h) before HI induction, its effect against neonatal hippocampal and striatal injury was clearly evident. Since
the human fetus is chronically exposed to placentally derived
hCG throughout its intrauterine life, hCG may potentially play
a physiological role in protecting the developing brain from
hypoxic-ischemic events that occur in utero or around the time
of birth.
In order to examine the in vivo neuroprotective actions of
hCG, we chose the Rice–Vannucci model of neonatal HI for this
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Figure 5 | Acute neuronal hCG exposure in vitro protects neurons against NMDA-mediated excitotoxic neurodegeneration. (A) Representative low-power digital
micrograph of MAP2 IR in DIV12 cultured, non-injured/non-hCG-treated, cortical neurons. (B–D) Representative digital micrographs of DIV12 cultured MAP2stained neuronal fibers 24 h following exposure to the NMDA-receptor agonist, IBO in the presence or absence of 2 or 20 IU/mL of hCG when hCG is administered
during and following IBO exposure. (E) Quantitative summary of the neuroprotective effect of acute hCG administration 24 h post-IBO administration. Percent
neurite degeneration was obtained as a function of the percent change in MAP2-IR from non-IBO control neurons. Scale bar = 220 µm. N = 4/condition.
Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human chorionic gonadotropin; IBO, ibotenic acid; IR, immunoreactivity.

study because this model has been widely used by researchers
to examine perinatal hypoxic-ischemic brain injury (49–51).
This model is unique in that its combination of unilateral
carotid occlusion and the systemic hypoxia produces the type
of hypoxic-ischemic brain injury in limbic (hippocampus)
and basal ganglia (striatum) regions that can be observed in
moderately to severely affected human neonates. However, this
injury model is only a functional model of neonatal injury and
Frontiers in Pediatrics | www.frontiersin.org

a limitation of this paradigm is that it does not truly simulate
the exact environmental and physiological parameters that are
seen in newborn HI. Furthermore, the degree of injury used in
our model does not induce robust tissue loss in the cortex (35).
This is also a limitation of the employed injury paradigm because
hypoxic-ischemic events in the human fetus/newborn do often
include the cerebral cortex (52). Perhaps the relatively small
amount (approximately 5%) (35) of cortical tissue loss after HI
9
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Figure 6 | Early (DIV3) high-dose hCG (100 IU/mL) exposure in vitro increases neuronal cell count and neurite sprouting. (A) Representative low-power
micrographs of DIV9 cortical neurons exposed to high-dose (10 and 100 IU/mL) hCG for 6 days and triple-stained with the neurite marker, MAP2, the neuronspecific marker, NeuN, and the astrocyte-specific marker, GFAP. Prolonged high concentrations of hCG resulted in large grouping of neurons with more complex
neurite processes surrounded by GFAP + astrocytes. In contrast, GFAP + astrocytes are nearly absent in non-hCG-treated cultures at DIV9. Small rectangular
inserts demonstrate a morphologically appearing GFAP + astrocyte (arrow) nearby a small group of NeuN + neurons. (B) A significant increase in MAP2 IR and
visible increases in neuronal sprouting were observed with greater than 2 IU/mL concentrations of hCG. High-dose hCG (100 IU/mL) appeared to qualitatively and
quantitatively increased NeuN + IR. Scale bar = 80 µm. N = 3/condition. Error bars show SE; *p < 0.05 and **p < 0.01. hCG, human chorionic gonadotropin; IR,
immunoreactivity.

induction observed explains the apparent lack of protection by
hCG against the cortical injury seen in this study.
Because hypothermia is known to reduce cerebral injury
after HI (45, 53) and central hCG receptors are known to affect
hypothalamic function (11) (a brain region importantly involved
in core body temperature regulation), we examined whether
hCG’s neuroprotective actions are attributed to a decrease in
body temperature. We confirmed the previous observation (54)
demonstrating that the body temperature of P7 neonates is highly
dependent on ambient temperature with rapid decreases in pup
temperature observed upon transfer of the neonates from 37 to
23°C; this effect has the potential to cause unwanted hypothermia
and alter the degree of cerebral injury. Importantly, we found that
IP administration of hCG does not affect the body temperature

Frontiers in Pediatrics | www.frontiersin.org

of healthy P7 neonates. Nevertheless, we did not examine
body temperature prior and after hCG injection in the injured
newborn mouse. Neonatal HI has been shown to decrease body
temperature in rodents (55). Therefore, we cannot rule out the
possibility that in the setting of HI, hCG potentiates a further
drop in body temperature which, in turn, could contribute to the
observed decrease in cerebral tissue loss. The potential contribution of hCG to mouse temperature during and after brain injury
should be explored in future studies in order to better understand
the neuroprotective effect of hCG found in this report.
Regarding the neonatal age examined, though induction of
HI sooner after birth (such as on postnatal 5) may have altered
the degree of cortical injury, we chose to follow a more common protocol for this model which involves induction of HI
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at P7. Of note, this age in a mouse most closely approximates
the developmental stage of late preterm human infants. Future
studies can examine brain injury at postnatal days before and
after this time point to assess whether hCG has differential
neuroprotective properties depending on the stage of brain
development. In this study, we also evaluated the brains of mouse
pups at 7 day post-injury. Since brain injury may potentially still
be evolving at this time, future studies should also examine the
long-term effects of hCG-mediated protection to affirm that the
neuroprotection is permanent. The reason that we also tested
hCG after HI induction was to determine whether there may be a
potential benefit for hCG administration to an infant postnatally
if an HI event occurs shortly after birth. However, our results
do not suggest that this is the case since we did not see any
reduction in brain injury when hCG was administered shortly
before or immediately after the induction of HI. Therefore, our
findings suggest that the neurological effects of hCG may only be
protective and not reparative. Perhaps once neurodegenerative
cellular processes have already been triggered, hCG exposure is
ineffective. It is also possible that hCG may offer beneficial effects
against HI-mediated cerebral injury that were not detected by
the hCG dose examined by our outcome measure (i.e., percentage of region-specific tissue loss). An alternative explanation of
the apparent lack of effect when administered right before or
after injury may be related to the mode of hCG administration.
Available human and animal data indicate that peak blood levels
of hCG are not achieved until at least 3 h following intramuscular
administration (which is known to be a faster route of delivery
to that of the IP route) (36, 56–59). Therefore, pharmacologically
relevant hCG actions on the brain may not begin until hours
after IP administration. hCG treatment immediately post HI or
1 h prior to neonatal injury may thus not accurately reflect the
full protective or potential restorative actions of this hormone in
the injured brain.
The difficulty over the years in defining a possible physiologic
role of hCG in human fetal development has been partially
attributed to a lack of suitable animal models. In humans, both
(placentally derived) hCG and (pituitary-derived) luteinizing
hormone (LH) bind to the same lutropin receptor (LHR) (1, 44).
Despite some biological and functional differences between these
hormones, hCG is highly analogous to LH and is often regarded
as a super powerful form of it. Lutropin receptors have been
identified in almost all species ranging from rodents to human
(60, 61). However, the presence of two different LHR ligands (LH
and hCG) is primarily a human phenomenon; most mammals
(except for humans, primates and horses) produce only LH
(44). Given that rodents do not naturally produce any type of
chorionic gonadotropin, rodent models are not relevant models
in distinguishing physiologic vs. pharmacologic levels of hCG;
unlike human fetuses/neonates, no dosage of hCG is physiological to a neonatal rodent. That said, we find that the 1,500 IU/kg
dose of hCG administered intraperitoneally in this study is a
close approximation to the hCG levels seen in human amniotic
fluid at term (43). We justify the use of the rodent model in this
study as a way to determine a possible neuroprotective role for
hCG in fetal development and not to establish the dosage that
would be required to achieve the effect.
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In the second part of the study, we directly explored the actions
of hCG on neuronal degeneration following in vitro neuronal
injury. The pathologic process of excitotoxicity occurs when
glutamate receptors, such as NMDA receptors, are overactivated;
excessive NMDA receptor stimulation is known to result in neuronal damage or death via rapid increases in intracellular calcium
(17, 62, 63). NMDA-mediated excitotoxicity plays a pathophysiological role in a wide range of other brain-injury paradigms
such as following focal or global cerebral ischemia (17, 63, 64). In
particular, glutamate-dependent excitotoxicity is a contributor
to the pro-degenerative mechanisms involved in neonatal HI
(63, 64). For example, HI-mediated brain injury in term-equivalent neonatal rats can be significantly reduced by pre-treatment
with the NMDA antagonist, MK801 (65, 66). Conversely,
overactivation of neuronal NMDA receptors in vitro by NMDA,
or in vitro and in vivo by the NMDA-agonist, IBO, results in
dose-dependent cerebral and neuronal degeneration (40, 67).
Given the above, we utilized the well-characterized model
of in vitro NMDA-mediated neuronal excitotoxicity to examine
whether hCG inhibits excitotoxic neuronal degeneration of
immature cortical and hippocampal neurons. In this model,
inhibition of excitotoxic neuronal degeneration is measured by
a decrease in LDH activity accompanied by a decrease in percentage of injury-triggered neurite loss. Importantly, our study
shows that hCG protected neurons against glutamate-mediated
excitotoxicity after prolonged hCG exposure as well as following acute drug exposure at the time of injury. Furthermore, our
results suggest that hCG likely blocks NMDA-mediated damage
to cell bodies as well as to neuronal processes, since degenerating
neurites do not release LDH (68). Therefore, acute and prolonged
in vitro hCG exposure protects neuronal cell bodies and their
processes from the degenerative effects of NMDA-receptor
overactivation. It is important to note, however, that cerebral
injury mediated via glutamate receptor activation is only a partial
contributor in the pathogenesis of cerebral HI and other cellular
mechanisms may contribute to the neuroprotective actions of
hCG as discussed below.
Remarkably, the amount of basal neuron and neurite density
increased when cortical cultures were exposed to hCG concentrations higher than 2 IU/mL. This result is consistent with
previous observations which indicate a dose-dependent increase
in the number of neurite-bearing dissociated rat brain neurons
following 3-day hCG exposure (6). Importantly, hCG contains
domains encountered in the protein family of neurotrophic glycoproteins (69). Thus, the observed hCG-dependent increases in
MAP2-stained fiber density may be indicative of hCG’s potential
neurotrophic actions on immature neurons. It will be important
in future studies to determine (a) which signaling pathways are
activated in the brain by hCG, (b) which receptors are required for
neuroprotective effects, and (c) whether neuroprotective effects
are due to cell autonomous vs. non-cell autonomous mechanisms.
All in all, the results of this study enhance our understanding of the potential physiologic role of hCG in neuroprotection
during brain development. The findings described in this report
suggest that hCG is capable of decreasing the injury of immature
neurons in vivo (prophylactically) and in vitro. In addition,
our findings show that peripheral hCG exposure prior to HI is
11
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required to decrease neuronal injury. This raises the possibility
that preterm infants, at higher than normal risk for HI-simulated
events postnatally, may benefit from prophylactic administration
of hCG. After all, preterm infants are prematurely deprived of
placental hCG exposure due to their early separation from placentally derived hormones. In other words, the developing brains
of preterm infants would naturally have had longer exposure to
hCG had they remained in utero until term. Future preclinical
studies should be performed to further evaluate whether hCG
supplementation to preterm infants at physiologically appropriate levels (to compensate for hCG deprivation) is beneficial. Of
important note, administration of hCG at 1,500 IU/kg results in
serum concentrations that have the potential to alter the levels
of other hormones such as testosterone. Thus, further preclinical
and clinical studies will be needed to determine whether there
is an hCG dose that is effective at providing neuroprotection to
injured neonates while producing minimal potentially adverse
systemic effects if it is to be considered for clinical use.
Our results also suggest that one of hCG’s mechanisms of
neuroprotection may be related to its inhibition of NMDAdependent excitotoxic neurodegeneration. Yet, it is important to
emphasize that hCG has multiple cellular targets in peripheral
tissues and brain (11, 44). Therefore, the neuroprotective actions
of hCG may be multifactorial and thus, it is unlikely that hCG’s
ability to reduce glutamate-mediated excitotoxic injury is its
only mechanism of action. For example, hCG may further
ameliorate the effects of cerebral injury in preterm and term
newborns by dampening systemic and/or central inflammation.
Emerging research in human reproduction demonstrates that
one of hCG’s important roles in pregnancy is to modulate the
maternal immune response and prevent the rejection and demise
of the semi-allogenic fetus (70). hCG modulates the phagocytic
action of macrophages, dampens the pro-inflammatory activity of T-lymphocytes, inhibits B-cell antibody production and
suppresses the synthesis of pro-inflammatory cytokines such as
TNF-α and interferon-gamma (71–77). hCG also increases the

synthesis of anti-inflammatory cytokines such as IL-10 (76), as
well as activates the production of pro-survival immunomodulatory cytokines such as leukemia inhibitory factor (78–82).
Interestingly, all the above hCG-regulated proteins play a very
important role in the pathogenesis of cerebral white matter
degeneration of the newborn, a condition that significantly contributes to the development of CP in term and preterm neonates
(83). Therefore, future studies should be performed to better
characterize the systemic and central-nervous-system-mediated
mechanisms that may contribute to the potentially beneficial
effects of this hormone against the effects of early cerebral injury.
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